Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marta Crispens, MD
Vanderbilt-Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Central Georgia Hematology Oncology Associates, P.C.
Macon, Georgia, United States
- Kentuckiana Cancer Institute
Louisville, Kentucky, United States
- the Jones Clinic
Germantown, Tennessee, United States
- Jackson-Madison County Hospital
Jackson, Tennessee, United States
- St. Thomas Health Services
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2003
- Primary completion
- 31 Mar 2009
- Completion
- 31 Mar 2009
- Last update posted
- 23 May 2012
- Registered enrollment
- 15
- Registry id
- NCT00653328
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.